Shuttle Pharmaceuticals Holdings, Inc. (SHPH)

0.4039 -0.0131 (-3.14%) At close: 04:00PM EDT

Shuttle Pharmaceuticals Holdings, Inc.

401 Professional Drive
Suite 260
Gaithersburg, MD 20879
United States
(240) 403-4212
https://www.shuttlepharma.com

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees: 8

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Anatoly Dritschilo M.D.	Co-Founder, CEO & Chairman of the Board	399.18k	N/A	1944
Mr. Peter Dale Dritschilo M.B.A., M.D.	President & COO	314.01k	N/A	1969
Dr. Milton Brown CSC, M.D., Ph.D.	Co-Founder & Director	N/A	N/A	1965
Mr. Michael P. Vander Hoek	CFO and VP of Operations & Regulatory	302.53k	N/A	1960
Dr. Tyvin A. Rich M.D.	Chief Clinical Officer & Chief Medical Officer	263.23k	N/A	1948
Dr. Mira Jung Ph.D.	Co-Founder & Chief Scientific Officer for Biology	N/A	N/A	1949
Mr. Gene Jung Esq.	General Counsel	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers . The company is based in Gaithersburg, Maryland.

Corporate governance

Shuttle Pharmaceuticals Holdings, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.